Cord Blood with PotentialCord blood is drawing attention due to its potential in regenerative medicine and cellular therapies, such as diseases that cannot be fully treated at present, like central nervous system disorders (hypoxic-ischemic encephalopathy, cerebral palsy, hearing loss and spinal cord injuries, etc.) as well as autoimmune disorders and autistic spectrum disorders and autism. It is also being used for the treatment of refractory blood diseases, such as leukemia and aplastic anemia.
Foundation research is confirming how cord blood repairs disorders and damage as stem cells in the cord blood migrate (home in on) to the damaged area of the brain, where they relieve inflammation, adjust immunity and activate other cells (cytocrine secretion). Currently, clinical trials on human volunteers are ongoing.
| Cerebral Palsy |
|---|
| Rate of incidence:2-3 out of 1,000 birth in Japan. (December 2013 announcement by investigation committee of Japan Obstetric Compensation System) |
| . |
| Autism |
|---|
| Rate of incidence:1-2 out of 100 birth in Japan. (Ministry of Health,Labour and Welfare) |
| . |
| Infant Hearing Loss |
|---|
| Rate of incidence:1-2 out of 1,000 birth in Japan. |
| . |
| Hypoxic Ischemic Encephalopathy |
|---|
| This is a brain disorder due to disrupted blood flow when there is a prolonged state of apparent death at time of birth.In some cases,this may develop to cerebral palsy. |
| . |
Cord Blood Registry, the leading private bank in the USA, has released a brief review regarding the research and clinical use of the newborn cord blood for various brain disorders including cerebral palsy, traumatic brain injury, stroke, etc. The review says that many scientists believe the cord blood cells have a potential to facilitate repair of the damaged brain tissue. For detail, please read
Newborn Stem Cells from Cord Blood and the Brain.
State of Affairs in Clinical Studies using Autologous Cord BloodDomestic:Reports up to March 2021
| Condition | Phase | Enrollment | Institution | Primary end date |
|---|---|---|---|---|
| Hypoxic-ischemic encephalopathy | Ⅰ | 6 | Osaka City University Hospital | Completed
(paper published) |
| Hypoxic-ischemic encephalopathy | Ⅱ | 15 | Osaka City University Hospital | Recruiting
(Estimated Primary Completion Date; March 2024) |
| Infantile
cerebral palsy （Autologous） |
Ⅰ | 6 | Kochi Medical School Hospital | Active, Not Recruiting |
| Infantile
cerebral palsy （Sibling） |
Ⅰ | 8 | Kochi Medical School Hospital | Recruiting
(Estimated Primary Completion Date; September 2024) |
Overseas
| Condition | Phase | Enrollment | Institution | Primary end date |
|---|---|---|---|---|
| Autism | Ⅱ | 29 | Sutter Health | Completed (paper published) |
| Autistic spectrum
disorder |
Ⅰ | 25 | Duke University | Completed (paper published) |
| Autistic spectrum
disorder |
Ⅱ | 165 | Duke University | Completed (paper published) |
| Autistic spectrum
disorder |
Ⅱ | 60 | Sheba Medical Center | Recruiting (Estimated Primary Completion Date; December 2024) |
| Cerebral palsy | Ⅱ | 63 | Duke University | Completed (paper published) |
| Cerebral palsy | Ⅰ/Ⅱ | 40 | Augusta University | Completed
(No paper published yet) |
| Cerebral palsy | Ⅱ | 20 | Texas University | Active, Not Recruiting |
| Cerebral palsy | Ⅱ | 72 | Sheba Medical Center | Recruiting (Estimated Primary Completion Date; December 2024) |
| Hypoxic ischemic
encephalopathy |
Ⅰ | 52 | Duke University | Completed
(paper published) |
| Hypoxic ischemic
encephalopathy |
Ⅱ | 36 | Duke University | Completed
(No paper published yet) |
| Hypoplastic
left heart syndrome |
Ⅰ | 10 | Mayo Clinic and
Other Facilities |
Completed
(paper published) |
| Hypoplastic
left heart syndrome |
Ⅱ | 100 | Mayo Clinic and
Other Facilities |
Recruiting (Estimated Primary Completion Date; December 2026) |
| Hypoplastic
left heart syndrome |
Ⅰ | 12 | Royal Children’s
Hospital |
Recruiting (Estimated Primary Completion Date; February 2021) |
| Congenital heart disease
and brain injuries |
Ⅰ/Ⅱ |
60 | Sheba Medical Center | Recruiting (Estimated Primary Completion Date; May 2021) |
| Type I diabetes | Ⅰ/Ⅱ | 15 | Florida University | Completed
(paper published) |
| Sensorineural
hearing loss |
Ⅰ | 11 | Florida Hospital | Completed
(paper published) |
All of the clinical trials listed above are using autologous cord blood. It is considered that the safety and efficiency are lowered when allogeneic cord blood is used.
